[{"id":"279f72d7-b141-456e-a82c-b2efb50e3de3","acronym":"BT7480-100","url":"https://clinicaltrials.gov/study/NCT05163041","created_at":"2021-12-20T16:53:57.547Z","updated_at":"2025-02-25T16:53:58.735Z","phase":"Phase 1/2","brief_title":"Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression","source_id_and_acronym":"NCT05163041 - BT7480-100","lead_sponsor":"BicycleTx Limited","biomarkers":" NECTIN4","pipe":" | ","alterations":" NECTIN4 expression","tags":["NECTIN4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NECTIN4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • BT7480"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 11/02/2021","start_date":" 11/02/2021","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-04"},{"id":"a7fa92a7-70a9-4cfd-bed6-1c623c642771","acronym":"BT8009-100","url":"https://clinicaltrials.gov/study/NCT04561362","created_at":"2021-01-18T21:47:25.968Z","updated_at":"2024-07-02T16:35:08.123Z","phase":"Phase 1/2","brief_title":"Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies","source_id_and_acronym":"NCT04561362 - BT8009-100","lead_sponsor":"BicycleTx Limited","biomarkers":" HER-2 • ER • ALK • PGR • ROS1 • NECTIN4","pipe":" | ","alterations":" EGFR mutation • ALK fusion • NECTIN4 expression","tags":["HER-2 • ER • ALK • PGR • ROS1 • NECTIN4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK fusion • NECTIN4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • zelenectide pevedotin (BT8009)"],"overall_status":"Recruiting","enrollment":" Enrollment 329","initiation":"Initiation: 07/17/2020","start_date":" 07/17/2020","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-23"},{"id":"f8bd5c27-03e2-4692-9f60-a75a628609a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01409135","created_at":"2021-01-19T04:30:18.499Z","updated_at":"2024-07-02T16:35:15.277Z","phase":"Phase 1","brief_title":"A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4","source_id_and_acronym":"NCT01409135","lead_sponsor":"Astellas Pharma Inc","biomarkers":" NECTIN4","pipe":" | ","alterations":" NECTIN4 expression","tags":["NECTIN4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NECTIN4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 07/11/2011","start_date":" 07/11/2011","primary_txt":" Primary completion: 04/27/2015","primary_completion_date":" 04/27/2015","study_txt":" Completion: 04/27/2015","study_completion_date":" 04/27/2015","last_update_posted":"2024-03-12"},{"id":"e1c7608c-7f2d-486a-b5af-4dd6bb37d415","acronym":"ASG-22CE-13-2","url":"https://clinicaltrials.gov/study/NCT02091999","created_at":"2021-01-19T08:19:26.317Z","updated_at":"2024-07-02T16:35:22.622Z","phase":"Phase 1","brief_title":"A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4","source_id_and_acronym":"NCT02091999 - ASG-22CE-13-2","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" NECTIN4","pipe":" | ","alterations":" NECTIN4 expression","tags":["NECTIN4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NECTIN4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Completed","enrollment":" Enrollment 213","initiation":"Initiation: 05/14/2014","start_date":" 05/14/2014","primary_txt":" Primary completion: 12/07/2022","primary_completion_date":" 12/07/2022","study_txt":" Completion: 12/07/2022","study_completion_date":" 12/07/2022","last_update_posted":"2024-01-23"},{"id":"86e13953-bb38-4a47-a05e-dfd0270162b5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05593107","created_at":"2022-10-25T13:56:24.748Z","updated_at":"2024-07-02T16:35:56.812Z","phase":"","brief_title":"68Ga-N188 PET/CT Imaging in Malignancy","source_id_and_acronym":"NCT05593107","lead_sponsor":"Peking University First Hospital","biomarkers":" NECTIN4","pipe":" | ","alterations":" NECTIN4 expression","tags":["NECTIN4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NECTIN4 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 203","initiation":"Initiation: 08/12/2022","start_date":" 08/12/2022","primary_txt":" Primary completion: 07/31/2025","primary_completion_date":" 07/31/2025","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2023-01-30"},{"id":"a74b2a6b-c53a-429a-a6e6-aeb6fe0acc78","acronym":"","url":"https://clinicaltrials.gov/study/NCT05216965","created_at":"2022-02-05T18:28:06.695Z","updated_at":"2024-07-02T16:36:08.717Z","phase":"Phase 1/2","brief_title":"A Clinical Study of 9MW2821 in Subjects With Advanced Malignant Solid Tumors","source_id_and_acronym":"NCT05216965","lead_sponsor":"Mabwell (Shanghai) Bioscience Co., Ltd.","biomarkers":" NECTIN4","pipe":" | ","alterations":" NECTIN4 expression","tags":["NECTIN4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NECTIN4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e bulumtatug fuvedotin (9MW2821)"],"overall_status":"Recruiting","enrollment":" Enrollment 208","initiation":"Initiation: 06/11/2022","start_date":" 06/11/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2022-06-15"},{"id":"6aff2aba-35a1-4846-94a9-768893c1feac","acronym":"","url":"https://clinicaltrials.gov/study/NCT05234606","created_at":"2022-02-10T13:52:58.124Z","updated_at":"2024-07-02T16:36:12.983Z","phase":"Phase 1/2","brief_title":"A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors","source_id_and_acronym":"NCT05234606","lead_sponsor":"Silverback Therapeutics","biomarkers":" HER-2 • NECTIN4","pipe":" | ","alterations":" HER-2 negative • NECTIN4 expression","tags":["HER-2 • NECTIN4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • NECTIN4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • SBT6290"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 03/31/2022","primary_completion_date":" 03/31/2022","study_txt":" Completion: 03/31/2022","study_completion_date":" 03/31/2022","last_update_posted":"2022-04-12"},{"id":"85862186-4d7e-480a-b17c-fdebf9d139f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT03932565","created_at":"2021-01-18T19:22:13.474Z","updated_at":"2024-07-02T16:36:38.551Z","phase":"Phase 1","brief_title":"Interventional Therapy Sequential With the Fourth-generation CAR-T Targeting Nectin4/FAP for Malignant Solid Tumors","source_id_and_acronym":"NCT03932565","lead_sponsor":"The Sixth Affiliated Hospital of Wenzhou Medical University","biomarkers":" NECTIN4 • CCL19 • FAP","pipe":" | ","alterations":" NECTIN4 expression • FAP expression","tags":["NECTIN4 • CCL19 • FAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NECTIN4 expression • FAP expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CAR-T Targeting Nectin4/FAP"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/13/2019","start_date":" 02/13/2019","primary_txt":" Primary completion: 06/30/2021","primary_completion_date":" 06/30/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2020-11-18"},{"id":"13608c35-003d-49d5-8068-aba26867f816","acronym":"","url":"https://clinicaltrials.gov/study/NCT03070990","created_at":"2021-03-08T17:01:27.042Z","updated_at":"2024-07-02T16:36:49.222Z","phase":"Phase 1","brief_title":"A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma","source_id_and_acronym":"NCT03070990","lead_sponsor":"Astellas Pharma Inc","biomarkers":" NECTIN4","pipe":" | ","alterations":" NECTIN4 expression","tags":["NECTIN4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NECTIN4 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Padcev (enfortumab vedotin-ejfv)"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/24/2017","start_date":" 04/24/2017","primary_txt":" Primary completion: 02/25/2019","primary_completion_date":" 02/25/2019","study_txt":" Completion: 02/25/2019","study_completion_date":" 02/25/2019","last_update_posted":"2020-03-04"}]